8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 6, 2009

BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)
Delaware	0-19879	11-3054851
(State or Other Jurisdiction	(Commission File Number)	(I.R.S. Employer
Of Incorporation)		Identification No.)
35 Wilbur Street
Lynbrook, NY 11563
(Address of Principal Executive Office) (Zip Code)
516.593.7000
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Introductory Comment

Throughout this Current Report on Form 8-K, the terms "we," "us," "our" and "Company" refer to BioSpecifics Technologies Corp.

ITEM 8.01.             OTHER EVENTS

Nasdaq Listing

On January 9, 2009 the Company’s common stock will be listed and commence trading on the Nasdaq Global Market under the symbol "BSTC." A press release announcing this development is being furnished as Exhibit 99.1 hereto.

2009 Annual Meeting Date

The Company will hold its 2009 annual meeting on June 17, 2009 at the New York offices of Bingham McCutchen LLP, located at 399 Park Avenue, New York, NY 10022. The deadline for stockholders to submit proposals to be included in our proxy statement with respect to the 2009 annual meeting is February 6, 2009.

ITEM 9.01.             FINANCIAL STATEMENTS AND EXHIBITS

(d)	Exhibits
99.1	Press Release dated January 6, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, each registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 6, 2009	BIOSPECIFICS TECHNOLOGIES CORP.
	(Registrant)
	/s/ Thomas L. Wegman
	Thomas L. Wegman
	President

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated January 6, 2009

EX-99.1

Exhibit 99.1

BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market

Lynbrook, N.Y., January 6, 2009 - BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, today announced that it has received notification from The NASDAQ Stock Market LLC that its common stock has been approved for listing on the NASDAQ Global Market. The Company's common stock will begin trading January 9, 2009 on NASDAQ at market open under the symbol "BSTC" and will end trading on the OTC Bulletin Board at the close of market on January 8, 2009.

"This listing on NASDAQ marks the culmination of a transformational year for us at BioSpecifics, and we believe it will greatly benefit our stockholders by enhancing our liquidity and overall visibility," stated Thomas L. Wegman, President of BioSpecifics. "In 2008, we announced positive Phase 3 clinical results for our collagenase product XIAFLEX™ for Dupuytren’s disease and our partner Auxilium initiated the Phase 2b trial for Peyronie’s disease. In addition, Auxilium just announced a major European licensing agreement with Pfizer, in which BioSpecifics will receive a share of both the upfront payment and sales and regulatory milestones. We are very much looking forward to further progress, including the filing with the U.S. Food and Administration of the Biologic License Application of XIAFLEX early this year."

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and partnered, injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease, and frozen shoulder (adhesive capsulitis). It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. Positive top line results from the Phase III clinical trials with XIAFLEX™ for treatment of Dupuytren’s disease were released in June 2008. Based on those positive Phase III results, Auxilium expects to file a Biologic License Application in early 2009.

Contact:

BioSpecifics Technologies Corp.
Thomas L. Wegman, President
(516) 593-7000
thomas_wegman@biospecifics.com